Literature DB >> 10478864

Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats.

G Jahnke1, M Marr, C Myers, R Wilson, G Travlos, C Price.   

Abstract

Melatonin (MEL) is a widely used, over-the-counter sleep aid, and it has putative contraceptive, antioxidant, antiaging, and anticancer effects. The developmental toxicity potential for repeated oral doses of MEL had not previously been evaluated. In the present studies, time-mated, Sprague-Dawley-derived (CD) rats were administered MEL or vehicle by gavage on gestation days (gd) 6-19. MEL-treated groups received 1-, 10-, 100-, 150-, or 200-mg/kg body weight/day in the screening study (15 rats/group), and 50, 100, or 200 mg/kg/day in the definitive study (25 rats/group). In both studies, maternal food/water consumption, body weight, and clinical signs were monitored at regular intervals throughout gestation. At termination (gd 20, both studies), maternal liver and gravid uterine weights, number of ovarian corpora lutea, conceptus survival, fetal sex, and fetal body weight were evaluated. Fetal morphological examination included external structures (both studies) as well as visceral and skeletal structures (definitive study). In the screening study, maternal serum levels of 17beta-estradiol, progesterone, prolactin, and luteinizing hormone were determined by radioimmunoassay, and mammary tissue was fixed, stained, and evaluated for percent glandular area within the fat pad. No maternal morbidity/mortality was found in either study. In the screening study, aversion to treatment (> or =100 mg/kg/day) and reduced maternal weight gain (> or =150 mg/kg/day) were noted, but reproductive/endocrine parameters and fetal development were not affected. In the definitive study, aversion to treatment was noted at > or =50 mg/kg/day, and mild sedation, reduced maternal food intake, and reduced body weight gain were found during initial treatment with 200 mg/kg/day. MEL had no effect on prenatal survival, fetal body weight, or incidences of fetal malformations/variations. Thus, in the definitive study, the maternal toxicity NOAEL and LOAEL were 100 and 200 mg/kg/day, respectively, and the developmental toxicity NOAEL was > or =200 mg/kg/day.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10478864     DOI: 10.1093/toxsci/50.2.271

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  63 in total

1.  Supplementation with low concentrations of melatonin improves nuclear maturation of human oocytes in vitro.

Authors:  Duo Wei; Cuilian Zhang; Culian Zhang; Juanke Xie; Xiaobing Song; Baoli Yin; Qi Liu; Lin Hu; Haoying Hao; Jiaxuan Geng; Peng Wang
Journal:  J Assist Reprod Genet       Date:  2013-06-06       Impact factor: 3.412

2.  Melatonin as an adjuvant therapy in patients with rheumatoid arthritis.

Authors:  Ahmet Korkmaz
Journal:  Br J Clin Pharmacol       Date:  2008-05-27       Impact factor: 4.335

3.  Melatonin Improves Mitochondrial Respiration in Syncytiotrophoblasts From Placentas of Obese Women.

Authors:  Kayla E Ireland; Alina Maloyan; Leslie Myatt
Journal:  Reprod Sci       Date:  2017-04-26       Impact factor: 3.060

4.  Melatonin-pretreated adipose-derived mesenchymal stem cells efficeintly improved learning, memory, and cognition in an animal model of Alzheimer's disease.

Authors:  Ebrahim Nasiri; Akram Alizadeh; Amaneh Mohammadi Roushandeh; Rouhollah Gazor; Nasrin Hashemi-Firouzi; Zoleikha Golipoor
Journal:  Metab Brain Dis       Date:  2019-05-25       Impact factor: 3.584

Review 5.  The Safety of Melatonin in Humans.

Authors:  Lars Peter Holst Andersen; Ismail Gögenur; Jacob Rosenberg; Russel J Reiter
Journal:  Clin Drug Investig       Date:  2016-03       Impact factor: 2.859

Review 6.  Inhibition of cysteine proteases in acute and chronic spinal cord injury.

Authors:  Swapan K Ray; Supriti Samantaray; Joshua A Smith; Denise D Matzelle; Arabinda Das; Naren L Banik
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

7.  Effects of antenatal, postpartum and post-weaning melatonin supplementation on blood pressure and renal antioxidant enzyme activities in spontaneously hypertensive rats.

Authors:  S K Lee; K N S Sirajudeen; Arunkumar Sundaram; Rahimah Zakaria; H J Singh
Journal:  J Physiol Biochem       Date:  2011-01-06       Impact factor: 4.158

Review 8.  Extrapineal melatonin: sources, regulation, and potential functions.

Authors:  Darío Acuña-Castroviejo; Germaine Escames; Carmen Venegas; María E Díaz-Casado; Elena Lima-Cabello; Luis C López; Sergio Rosales-Corral; Dun-Xian Tan; Russel J Reiter
Journal:  Cell Mol Life Sci       Date:  2014-02-20       Impact factor: 9.261

9.  The inhibition of apoptosis by melatonin in VSC4.1 motoneurons exposed to oxidative stress, glutamate excitotoxicity, or TNF-alpha toxicity involves membrane melatonin receptors.

Authors:  Arabinda Das; Misty McDowell; Matthew J Pava; Joshua A Smith; Russel J Reiter; John J Woodward; Abhay K Varma; Swapan K Ray; Naren L Banik
Journal:  J Pineal Res       Date:  2010-01-17       Impact factor: 13.007

10.  Rapid Communication: Maternal melatonin implants improve fetal oxygen supply and body weight at term in sheep pregnancies.

Authors:  Francisco Sales; Oscar A Peralta; Eileen Narbona; Sue McCoard; Antonio González-Bulnes; Victor H Parraguez
Journal:  J Anim Sci       Date:  2019-02-01       Impact factor: 3.159

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.